Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Combined With Apatinib and Chemoradiotherapy for Locally Advanced Pancreatic Cancer
NCT04723030Phase 2Unknown
- Sponsor
- Peking University
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Peking University. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04723030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723030.